- Home
- / Cascadian Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Cascadian Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$4 M
FY, 2012
CreditSafe Score
?
Score changed on Jun 13, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 145.0K | 4.0M | |||||
| General and administrative expense | 6.9M | 6.5M | 8.0M | 9.0M | 9.3M | 17.6M | 14.1M |
| Operating expense total | 24.8M | 28.5M | 41.2M | 50.8M | 32.8M | 45.1M | 58.1M |
| EBIT | (24.7M) | (28.5M) | (41.2M) | (50.8M) | (32.8M) | (64.8M) | (58.1M) |
| EBIT margin, % | -17033.8% | -712.5% | |||||
| Investment income | 128.0K | ||||||
| Interest expense | 631.0K | 308.7K | 872.0K | 208.0K | 222.0K | 1.2M | |
| Pre tax profit | (42.7M) | (3.4M) | (38.8M) | (50.0M) | (32.6M) | (64.6M) | (56.9M) |
| Income tax expense | (6.9M) | ||||||
| Net Income | (42.7M) | (3.4M) | (38.8M) | (50.0M) | (32.6M) | (57.7M) | (56.9M) |